This compound is a critical pharmaceutical intermediate specifically designed for the synthesis of SGLT2 inhibitors, a class of anti-diabetic drugs used to treat type 2 diabetes mellitus. It serves as a key building block in the production of dapagliflozin and related analogs, which function by inhibiting renal glucose reabsorption, thereby promoting glucosuria and lowering blood glucose levels. The solvate structure with 2-butyne-1,4-diol enhances stability and crystallinity, facilitating purification and handling in industrial-scale manufacturing. Beyond diabetes treatment, it supports research into SGLT2-related cardiovascular and renal protective therapies, as SGLT2 inhibitors have demonstrated benefits in heart failure and chronic kidney disease management. It is also utilized in the development of novel SGLT1/SGLT2 dual inhibitors and structural analogs for pharmacological studies.

GHS Classification: Skin Irritation (Category 2), Eye Irritation (Category 2A), Specific Target Organ Toxicity (Single Exposure, Category 3) Hazards: Causes skin irritation; causes serious eye irritation; may cause respiratory irritation. No significant acute toxicity data exists, but prolonged or repeated exposure may lead to allergic skin reactions or respiratory sensitization.

Handling: Use in a fume hood; wear nitrile gloves, safety goggles, and a lab coat. Avoid inhalation of dust, skin/eye contact, and ingestion. Ensure adequate ventilation in the workplace.

First Aid: Skin: Rinse with soap and water for 15 minutes; remove contaminated clothing. Eyes: Flush with plenty of water for 15 minutes; seek medical attention if irritation persists. Inhalation: Move to fresh air; if breathing difficulties occur, get medical help. Ingestion: Rinse mouth; do not induce vomiting; consult a physician.

Storage & Disposal: Store sealed at 2–8 °C, protected from light. Dispose of as hazardous waste per local regulations; do not release to the environment.